Aceto Corp. said Monday it plans to begin selling a medicine to treat migraines.
The Port Washington-based manufacturer of drugs and chemicals said it would launch zolmitriptan tablets, a generic version of Zomig from IPR Pharamaceuticals Inc.
The drug information provider IMS Health estimated U.S. sales of zolmitriptan totaled $49 million last year.
The generic drug will be sold by Aceto’s Rising Pharmaceuticals subsidiary, which is based in New Jersey.
Aceto made the announcement after the stock market opening. The company’s stock fell 13 cents to $23.46 on the Nasdaq Stock Market Monday.